Highly read articles on psoriatic arthritis highlight news in biologics, biosimilar therapies

Biologics, and particularly biosimilars, have been in the news about psoriatic arthritis and other rheumatic, dermatologic and gastrological diseases.

Much of the recently published research about psoriatic arthritis has focused on developments in biologics and biosimilar medications.

Tofacitinib meets primary endpoints in psoriatic arthritis phase 3 trial

Pfizer announced its Oral Psoriatic Arthritis TriaL (OPAL) BROADEN study of 5-mg and 10-mg daily tofacitinib for the treatment of adult patients with active psoriatic arthritis met primary efficacy goals of ACR20 response superior to placebo at 3 months, according to a press release. Read more.

FDA approves biosimilar to infliximab

The FDA has approved Celltrion’s infliximab-dyyb, a biosimilar to infliximab, for multiple indications, including rheumatoid arthritis in combination with methotrexate, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn’s disease in adults and children older than 6 years, and patients with moderate to severe ulcerative colitis who inadequately responded to conventional treatment. Read more.

Incidence of psoriatic arthritis among patients with psoriasis may be higher than estimated

Previous estimates on the incidence of psoriatic arthritis among patients with psoriasis may not accurately reflect the prevalence of disease, according to recently published research that noted patients with uveitis, nail pitting and low levels of education may have a higher risk for developing psoriatic arthritis. Read more.

Remission, minimal disease activity may be possible with TNFi for some patients with axial psoriatic arthritis

Some patients with axial psoriatic arthritis were able to achieve minimal disease activity and remission with tumor necrosis factor inhibitors, according to the results of a study. Read more.

High rate of drug survival, reduced glucocorticoid use seen with tumor necrosis factor inhibitors for patients with psoriatic arthritis

Patients with psoriatic arthritis who received tumor necrosis factor inhibitors, including adalimumab, etanercept and infliximab, had a high likelihood of drug continuation and reduced use of glucocorticoids after 4 years, according to recently published data. Read more.